Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New 3D test system for breast cancer radiosensitizing drugs

23.06.2015

Radiation therapy is an important part of breast cancer treatment. Sometimes, however, tumor cells become increasingly resistant to radiation damage. Now, scientists of Helmholtz Zentrum München have developed a 3D microtissue-based screening system which, for the first time, enables them to test which chemotherapeutic drugs can resensitize breast cancer cells to radiation.

The team of researchers led by Dr. Nataša Anastasov, head of the research group ‘Personalized Radiation Therapy’ at the Institute of Radiation Biology, created multicellular three-dimensional spheroids containing a mix of breast cancer cells and connective tissue cells.


Picture: Hanging Drop System for the production of 3D micro tissue

Source: InSphero AG (2014)

As Anastasov explained, “In conventional cell culture, cell growth is two dimensional, which does not adequately reproduce the characteristics of a tumor in the living organism.” Using the new screening system, the scientists can treat the cancer cells both with various chemical compounds and with radiation to determine the effects – and that in 3D.

In their study the researchers collaborated closely with the ‘Assay Development and Screening Platform’ at Helmholtz Zentrum München and the Munich-based Sirion Biotech GmbH and the Swiss InSphero AG.

The trick: fluorescent cells in hanging drops

“In our system, up to 96 wells containing microtissue spheroids can be simultaneously monitored by a computer,” said co-author Dr. Ines Höfig, explaining the fundamental principle. “For this purpose, the 3D-microtissue spheroids were grown in a hanging drop culture on the underside of a special perforated plate. After a few days, these were transferred onto an assay plate.”

Her colleague Vanja Radulović added: “Because the breast tumor cells and the connective tissue cells have been labeled with different fluorescent markers, they fluoresce in different colors. A software program can thus capture precisely how each of the spheroids reacts to the treatment.”

To confirm their method, the scientists tested the properties of several drugs which are already used in tumor therapy. The drug vinblastine proved to be the most effective in combination with radiation. In the future, the researchers plan to expand their system by adding other components of the tumor environment such as stromal or immune cells in order to optimally simulate the situation in the patient.

Prof. Dr. Michael Atkinson, director of the Institute of Radiation Biology, views the findings of his colleagues with optimism: “For the first time a convenient 3D test for high throughput screening is available with which new drug compounds developed to resensitize tumor cells to radiation treatment can be tested. This will speed up future initiatives for drug development and will also enable the screening of established drugs in combination with radiation.”


Further Information

Background:
The rapid evolution of resistance to both conventional and small molecule therapies is a challenging problem in oncology. One approach to overcome resistance is to use combinatorial treatments that exploit their synergies. The combination of chemotherapy and radiation treatment is a potentially effective combinatorial procedure, although the optimal mix has not been identified. A major drawback in identifying potentially radiation-sensitizing active agents is the lack of high throughput screening (HTS) vehicles. These are needed to replace conventional clonogenic survival assays of radiation treatment as these are too time consuming to operate in a first-pass screening mode. Moreover, there are growing concerns that monolayer and monotypic cellular screening assays may not effectively reproduce the response of a three-dimensional solid tumor to pharmacological compounds.

Original Publication:
Anastasov, N. et al. (2015). A 3D-microtissue-based phenotypic screening of radiation resistant tumor cells with synchronized chemotherapeutic treatment, BMC Cancer, DOI: 10.1186/s12885-015-1481-9

As German Research Center for Environmental Health, Helmholtz Zentrum München pursues the goal of developing personalized medical approaches for the prevention and therapy of major common diseases such as diabetes mellitus and lung diseases. To achieve this, it investigates the interaction of genetics, environmental factors and lifestyle. The Helmholtz Zentrum München has about 2,300 staff members and is headquartered in Neuherberg in the north of Munich. Helmholtz Zentrum München is a member of the Helmholtz Association, a community of 18 scientific-technical and medical-biological research centers with a total of about 37,000 staff members.

The research of the Institute of Radiation Biology (ISB) focuses on understanding the effects of low dose radiation exposure and on studies to increase the effectiveness and specificity of tumor radiotherapy. The research program is carried out by four interlinked research groups. The ISB is part of the Department of Radiation Sciences (DRS).

Contact for the media:
Department of Communication, Helmholtz Zentrum München – German Research Center for Environmental Health (GmbH), Ingolstädter Landstr. 1, 85764 Neuherberg - Phone: +49-(0)89-3187-2238 - Fax: +49 89-3187-3324 - Email: presse@helmholtz-muenchen.de

Scientific contact at Helmholtz Zentrum München:
Dr. Nataša Anastasov, Institute of Radiation Biology, Helmholtz Zentrum München - German Research Center for Environmental Health (GmbH), Ingolstädter Landstr. 1, 85764 Neuherberg - Phone: +49-(0)89-3187-3798 - Fax: +49-(0)89-3187-3378 - E-Mail: natasa.anastasov@helmholtz-muenchen.de

Weitere Informationen:

http://www.helmholtz-muenchen.de/en/index.html - Website Helmholtz Zentrum München
http://www.helmholtz-muenchen.de/en/isb/index.html - Website Institute of Radiation Biology
http://www.helmholtz-muenchen.de/aktuelles/pressemitteilungen/2015/index.html - Press Releases of the Helmholtz Zentrum München

Helmholtz Kommunikation | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt

More articles from Life Sciences:

nachricht Researchers identify potentially druggable mutant p53 proteins that promote cancer growth
09.12.2016 | Cold Spring Harbor Laboratory

nachricht Plant-based substance boosts eyelash growth
09.12.2016 | Fraunhofer-Institut für Angewandte Polymerforschung IAP

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Electron highway inside crystal

Physicists of the University of Würzburg have made an astonishing discovery in a specific type of topological insulators. The effect is due to the structure of the materials used. The researchers have now published their work in the journal Science.

Topological insulators are currently the hot topic in physics according to the newspaper Neue Zürcher Zeitung. Only a few weeks ago, their importance was...

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Researchers identify potentially druggable mutant p53 proteins that promote cancer growth

09.12.2016 | Life Sciences

Scientists produce a new roadmap for guiding development & conservation in the Amazon

09.12.2016 | Ecology, The Environment and Conservation

Satellites, airport visibility readings shed light on troops' exposure to air pollution

09.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>